Efficacy and safety of Cladribine as a therapeutic option in multiple sclerosis patients over 50 years of age: A real-world study
- 15 October 2025
- journal article
- Published by Elsevier in Journal of the Neurological Sciences
- Vol. 478, 123727
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Exit strategies in patients with stable MS: Cost-effectiveness of extended interval dosing of ocrelizumab and natalizumab versus de-escalating to cladribineMultiple Sclerosis and Related Disorders, 2025
- Narrative Review on the Use of Cladribine Tablets as Exit Therapy for Stable Elderly Patients with Multiple SclerosisNeurology and Therapy, 2024
- Population-Based Estimates for the Prevalence of Multiple Sclerosis in the United States by Race, Ethnicity, Age, Sex, and Geographic RegionJAMA Neurology, 2023
- Safety and efficacy of cladribine in multiple sclerosis: a systematic review and meta-analysisNeurological Sciences, 2023
- Immunosenescence in multiple sclerosis: the identification of new therapeutic targetsAutoimmunity Reviews, 2021
- Multiple sclerosis and aging: comorbidity and treatment challengesMultiple Sclerosis and Related Disorders, 2021
- Treatment of Multiple Sclerosis: A ReviewThe American Journal of Medicine, 2020
- Cladribine Tablets 35 mg/kg Is Efficacious in Patients Aged Above and Below 45 Years with Relapsing Multiple Sclerosis in the Clarity StudyMultiple Sclerosis and Related Disorders, 2018
- Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteriaThe Lancet Neurology, 2018
- Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysisThe Lancet Neurology, 2011